Pre-Case Assessment: Test Your Baseline Knowledge
1
At what eGFR threshold should anemia evaluation be initiated in patients with CKD?
A) eGFR less than 90 mL/min/1.73m²
B) eGFR less than 60 mL/min/1.73m²
C) eGFR less than 30 mL/min/1.73m²
D) Only when symptoms of anemia develop
Correct Answer: B
KDIGO Guideline: Anemia evaluation should be initiated when eGFR falls below sixty milliliters per minute per 1.73 square meters (CKD G3-G5). Anemia becomes increasingly common as kidney function declines. Evaluation includes CBC, iron studies (ferritin, transferrin saturation), vitamin B12, and folate levels.
📚 Reference: CKD Anemia Management
KDIGO Guideline: Anemia evaluation should be initiated when eGFR falls below sixty milliliters per minute per 1.73 square meters (CKD G3-G5). Anemia becomes increasingly common as kidney function declines. Evaluation includes CBC, iron studies (ferritin, transferrin saturation), vitamin B12, and folate levels.
📚 Reference: CKD Anemia Management
2
What is the target hemoglobin range for erythropoiesis-stimulating agent (ESA) therapy in patients with CKD?
A) 9-10 g/dL
B) 10-11.5 g/dL
C) 12-13 g/dL
D) Normalize to 14-16 g/dL
Correct Answer: B
Evidence Base: Target hemoglobin of ten to 11.5 grams per deciliter balances symptom improvement with cardiovascular safety. Targeting higher hemoglobin (greater than thirteen grams per deciliter) increases risk of stroke, thrombosis, and cardiovascular events as shown in TREAT and CHOIR trials. Avoid ESA initiation when hemoglobin is greater than ten grams per deciliter.
Evidence Base: Target hemoglobin of ten to 11.5 grams per deciliter balances symptom improvement with cardiovascular safety. Targeting higher hemoglobin (greater than thirteen grams per deciliter) increases risk of stroke, thrombosis, and cardiovascular events as shown in TREAT and CHOIR trials. Avoid ESA initiation when hemoglobin is greater than ten grams per deciliter.
3
Which iron parameter values indicate adequate iron stores for erythropoiesis in CKD patients?
A) Ferritin greater than 100 ng/mL only
B) Ferritin greater than 100 ng/mL AND transferrin saturation (TSAT) greater than 20%
C) Ferritin greater than 500 ng/mL only
D) TSAT greater than 50%
Correct Answer: B
Iron Parameters: Adequate iron stores require both ferritin greater than one hundred nanograms per milliliter AND TSAT greater than twenty percent. For ESA therapy, target ferritin greater than 200-500 ng/mL and TSAT greater than thirty percent to ensure adequate iron availability for erythropoiesis. TSAT less than twenty percent indicates functional iron deficiency even if ferritin is normal.
Iron Parameters: Adequate iron stores require both ferritin greater than one hundred nanograms per milliliter AND TSAT greater than twenty percent. For ESA therapy, target ferritin greater than 200-500 ng/mL and TSAT greater than thirty percent to ensure adequate iron availability for erythropoiesis. TSAT less than twenty percent indicates functional iron deficiency even if ferritin is normal.
Case Presentation
Patient: Mrs. Dorothy Williams, 72-year-old woman
Chief Complaint: Increasing fatigue and shortness of breath with exertion
History: Progressive fatigue over three months, now unable to climb stairs without resting. Previously walked one mile daily, now limited to one block. Denies chest pain, palpitations, or syncope. Some mild dyspnea with exertion. No bleeding noted. Good appetite but reports decreased exercise tolerance affecting quality of life.
Past Medical History: CKD G4 (eGFR 22 mL/min/1.73m²) secondary to hypertensive nephrosclerosis, hypertension, coronary artery disease, osteoarthritis
Medications: Lisinopril 20mg daily, amlodipine 10mg daily, atorvastatin 40mg daily, aspirin 81mg daily, furosemide 40mg daily
Social History: Lives independently, retired teacher, no smoking or alcohol
📊 Clinical Assessment Questions
4
Laboratory results show hemoglobin 8.5 g/dL, MCV 88 fL (normocytic), ferritin 45 ng/mL, TSAT 15%, creatinine 3.2 mg/dL. What is the most likely cause of anemia?
A) Folate deficiency
B) Vitamin B12 deficiency
C) Anemia of CKD with absolute iron deficiency
D) Gastrointestinal bleeding
Correct Answer: C
Diagnosis: This patient has anemia of CKD (hemoglobin 8.5 g/dL with eGFR 22) complicated by absolute iron deficiency (ferritin 45 ng/mL, TSAT 15%). CKD G4-G5 causes anemia due to decreased erythropoietin production. Iron deficiency (ferritin less than 100 ng/mL, TSAT less than 20%) must be corrected before considering ESA therapy. The normocytic anemia pattern is typical for CKD. While GI bleeding should be excluded given aspirin use and low iron stores, the clinical picture is most consistent with CKD anemia plus iron deficiency.
Diagnosis: This patient has anemia of CKD (hemoglobin 8.5 g/dL with eGFR 22) complicated by absolute iron deficiency (ferritin 45 ng/mL, TSAT 15%). CKD G4-G5 causes anemia due to decreased erythropoietin production. Iron deficiency (ferritin less than 100 ng/mL, TSAT less than 20%) must be corrected before considering ESA therapy. The normocytic anemia pattern is typical for CKD. While GI bleeding should be excluded given aspirin use and low iron stores, the clinical picture is most consistent with CKD anemia plus iron deficiency.
5
What is the most appropriate initial management for this patient's anemia?
A) Start erythropoiesis-stimulating agent immediately
B) Initiate oral or IV iron supplementation to replete iron stores first
C) Transfuse two units packed red blood cells
D) Increase dietary iron intake only
Correct Answer: B
Management Principle: Iron deficiency must be corrected before initiating ESA therapy. ESAs require adequate iron availability to stimulate effective erythropoiesis. With ferritin 45 ng/mL and TSAT 15%, this patient has absolute iron deficiency. Oral iron (ferrous sulfate 325mg three times daily) or IV iron (iron sucrose, ferumoxytol, or iron dextran) can be used. IV iron is more effective in CKD, especially if eGFR less than 30 or poor oral tolerance. Target ferritin greater than 100-200 ng/mL and TSAT greater than 20% before starting ESA. Transfusion reserved for symptomatic severe anemia or cardiovascular instability. Dietary iron alone is insufficient.
Management Principle: Iron deficiency must be corrected before initiating ESA therapy. ESAs require adequate iron availability to stimulate effective erythropoiesis. With ferritin 45 ng/mL and TSAT 15%, this patient has absolute iron deficiency. Oral iron (ferrous sulfate 325mg three times daily) or IV iron (iron sucrose, ferumoxytol, or iron dextran) can be used. IV iron is more effective in CKD, especially if eGFR less than 30 or poor oral tolerance. Target ferritin greater than 100-200 ng/mL and TSAT greater than 20% before starting ESA. Transfusion reserved for symptomatic severe anemia or cardiovascular instability. Dietary iron alone is insufficient.
6
After iron repletion (ferritin now 250 ng/mL, TSAT 28%), hemoglobin remains 8.8 g/dL. The patient continues to report fatigue limiting activities. What is the next step?
A) Transfuse packed red blood cells to hemoglobin greater than 10 g/dL
B) Initiate erythropoiesis-stimulating agent therapy with target hemoglobin 10-11.5 g/dL
C) Continue observation without treatment
D) Refer for bone marrow biopsy
Correct Answer: B
ESA Initiation: With adequate iron stores (ferritin 250 ng/mL, TSAT 28%), persistent anemia (hemoglobin 8.8 g/dL), and significant symptoms affecting quality of life, ESA therapy is appropriate. Options include epoetin alfa (Epogen, Procrit) typically started at 50-100 units/kg subcutaneously weekly or darbepoetin alfa (Aranesp) 0.45 mcg/kg subcutaneously every two weeks. Target hemoglobin is ten to 11.5 grams per deciliter. Monitor hemoglobin every two to four weeks and adjust dose to achieve target gradually. Transfusion is not indicated for hemoglobin 8.8 g/dL without cardiovascular instability. Bone marrow biopsy is not needed with clear CKD etiology.
ESA Initiation: With adequate iron stores (ferritin 250 ng/mL, TSAT 28%), persistent anemia (hemoglobin 8.8 g/dL), and significant symptoms affecting quality of life, ESA therapy is appropriate. Options include epoetin alfa (Epogen, Procrit) typically started at 50-100 units/kg subcutaneously weekly or darbepoetin alfa (Aranesp) 0.45 mcg/kg subcutaneously every two weeks. Target hemoglobin is ten to 11.5 grams per deciliter. Monitor hemoglobin every two to four weeks and adjust dose to achieve target gradually. Transfusion is not indicated for hemoglobin 8.8 g/dL without cardiovascular instability. Bone marrow biopsy is not needed with clear CKD etiology.
7
After starting darbepoetin 60 mcg every two weeks, hemoglobin increases to 12.8 g/dL over three months. What adjustment should be made?
A) Continue same dose to maintain higher hemoglobin
B) Increase dose to target hemoglobin 13-14 g/dL
C) Reduce dose by 25% or hold until hemoglobin decreases to 11-11.5 g/dL
D) Discontinue ESA therapy completely
Correct Answer: C
ESA Dose Adjustment: Hemoglobin 12.8 g/dL exceeds target of ten to 11.5 grams per deciliter. Reduce dose by twenty-five percent or hold ESA temporarily until hemoglobin falls to 11-11.5 g/dL, then resume at lower dose. Maintaining hemoglobin above 11.5-12 g/dL increases cardiovascular risk including stroke and thrombotic events. Never target "normal" hemoglobin. The goal is to reduce symptoms while minimizing ESA exposure and cardiovascular risk. Some patients may maintain stable hemoglobin after ESA discontinuation if iron stores remain adequate.
ESA Dose Adjustment: Hemoglobin 12.8 g/dL exceeds target of ten to 11.5 grams per deciliter. Reduce dose by twenty-five percent or hold ESA temporarily until hemoglobin falls to 11-11.5 g/dL, then resume at lower dose. Maintaining hemoglobin above 11.5-12 g/dL increases cardiovascular risk including stroke and thrombotic events. Never target "normal" hemoglobin. The goal is to reduce symptoms while minimizing ESA exposure and cardiovascular risk. Some patients may maintain stable hemoglobin after ESA discontinuation if iron stores remain adequate.
8
A patient on ESA therapy has ferritin 600 ng/mL but TSAT is 18% with suboptimal hemoglobin response. This indicates:
A) Iron overload requiring cessation of iron therapy
B) Functional iron deficiency requiring IV iron despite elevated ferritin
C) Adequate iron stores, increase ESA dose only
D) Inflammation masking true iron status
Correct Answer: B
Functional Iron Deficiency: High ferritin (greater than 500 ng/mL) with low TSAT (less than 20%) indicates functional iron deficiency. Iron stores exist but are not available for erythropoiesis, often due to hepcidin-mediated iron sequestration or rapid consumption by ESA-stimulated erythropoiesis. This is common in CKD patients on ESA therapy. Treatment is IV iron supplementation despite elevated ferritin. Target TSAT greater than thirty percent. Monitor ferritin to avoid true iron overload (ferritin should stay below 500-800 ng/mL). Functional iron deficiency explains ESA hyporesponsiveness in many patients.
Functional Iron Deficiency: High ferritin (greater than 500 ng/mL) with low TSAT (less than 20%) indicates functional iron deficiency. Iron stores exist but are not available for erythropoiesis, often due to hepcidin-mediated iron sequestration or rapid consumption by ESA-stimulated erythropoiesis. This is common in CKD patients on ESA therapy. Treatment is IV iron supplementation despite elevated ferritin. Target TSAT greater than thirty percent. Monitor ferritin to avoid true iron overload (ferritin should stay below 500-800 ng/mL). Functional iron deficiency explains ESA hyporesponsiveness in many patients.
9
Which of the following is an absolute contraindication to ESA therapy?
A) Hypertension
B) History of stroke two years ago
C) Active malignancy receiving chemotherapy
D) Diabetes mellitus
Correct Answer: C
Contraindications: Active malignancy is an absolute contraindication to ESA therapy because ESAs may promote tumor growth and reduce survival in cancer patients. ESAs should not be used in patients receiving chemotherapy for curative intent. Relative contraindications include uncontrolled hypertension (must control BP before starting ESA), history of stroke (increased risk with ESA), and prior thrombotic events. Hypertension and diabetes are not contraindications if well-controlled. Monitor blood pressure closely after ESA initiation as it may worsen hypertension.
Contraindications: Active malignancy is an absolute contraindication to ESA therapy because ESAs may promote tumor growth and reduce survival in cancer patients. ESAs should not be used in patients receiving chemotherapy for curative intent. Relative contraindications include uncontrolled hypertension (must control BP before starting ESA), history of stroke (increased risk with ESA), and prior thrombotic events. Hypertension and diabetes are not contraindications if well-controlled. Monitor blood pressure closely after ESA initiation as it may worsen hypertension.
10
What is the most appropriate hemoglobin threshold for transfusion in a stable CKD patient without active bleeding or cardiovascular symptoms?
A) Less than 10 g/dL
B) Less than 8 g/dL
C) Less than 7 g/dL or symptomatic
D) Any hemoglobin below normal range
Correct Answer: C
Transfusion Thresholds: For stable patients without cardiovascular disease or active bleeding, restrictive transfusion strategy with threshold of seven grams per deciliter is recommended. For patients with cardiovascular disease or symptoms (chest pain, dyspnea, tachycardia), threshold may be eight grams per deciliter. Transfusions should be used judiciously in CKD due to risks including iron overload, alloimmunization (problematic for future transplant candidates), infection, and volume overload. ESA therapy and iron supplementation are preferred for chronic anemia management.
Transfusion Thresholds: For stable patients without cardiovascular disease or active bleeding, restrictive transfusion strategy with threshold of seven grams per deciliter is recommended. For patients with cardiovascular disease or symptoms (chest pain, dyspnea, tachycardia), threshold may be eight grams per deciliter. Transfusions should be used judiciously in CKD due to risks including iron overload, alloimmunization (problematic for future transplant candidates), infection, and volume overload. ESA therapy and iron supplementation are preferred for chronic anemia management.
11
A patient on ESA therapy has been stable but now requires increasing ESA doses to maintain target hemoglobin. Which cause of ESA hyporesponsiveness should be evaluated first?
A) Iron deficiency (check ferritin and TSAT)
B) Pure red cell aplasia
C) Bone marrow infiltration
D) Hemolysis
Correct Answer: A
ESA Hyporesponsiveness: Iron deficiency is the most common cause of ESA hyporesponsiveness. Check ferritin and TSAT first. Other common causes include: infection or inflammation (check CRP), blood loss (occult GI bleeding, menstruation), vitamin B12 or folate deficiency, hyperparathyroidism (check PTH), and inadequate dialysis (if on dialysis). Less common causes include pure red cell aplasia (very rare, presents with severe anemia and absent reticulocytes), hemolysis, bone marrow disorders, or aluminum toxicity (rare now). Systematic evaluation of common causes should precede investigation of rare etiologies.
ESA Hyporesponsiveness: Iron deficiency is the most common cause of ESA hyporesponsiveness. Check ferritin and TSAT first. Other common causes include: infection or inflammation (check CRP), blood loss (occult GI bleeding, menstruation), vitamin B12 or folate deficiency, hyperparathyroidism (check PTH), and inadequate dialysis (if on dialysis). Less common causes include pure red cell aplasia (very rare, presents with severe anemia and absent reticulocytes), hemolysis, bone marrow disorders, or aluminum toxicity (rare now). Systematic evaluation of common causes should precede investigation of rare etiologies.
12
What is the preferred route of iron administration in non-dialysis CKD patients with eGFR less than 30 mL/min/1.73m²?
A) Oral iron is always preferred
B) Intravenous iron is more effective and better tolerated
C) Intramuscular iron injections
D) Dietary iron only
Correct Answer: B
IV Iron Advantage: In advanced CKD (eGFR less than 30), IV iron is more effective than oral iron for several reasons: better absorption (oral iron absorption is impaired in CKD due to hepcidin), better tolerance (fewer GI side effects), and more rapid repletion. IV iron formulations include iron sucrose, ferumoxytol, iron dextran, ferric gluconate, and ferric carboxymaltose. Oral iron can be tried first in earlier CKD stages (G3a-G3b) but IV iron is preferred in G4-G5. IM iron is painful and not recommended. Dietary iron alone is insufficient to treat iron deficiency anemia.
IV Iron Advantage: In advanced CKD (eGFR less than 30), IV iron is more effective than oral iron for several reasons: better absorption (oral iron absorption is impaired in CKD due to hepcidin), better tolerance (fewer GI side effects), and more rapid repletion. IV iron formulations include iron sucrose, ferumoxytol, iron dextran, ferric gluconate, and ferric carboxymaltose. Oral iron can be tried first in earlier CKD stages (G3a-G3b) but IV iron is preferred in G4-G5. IM iron is painful and not recommended. Dietary iron alone is insufficient to treat iron deficiency anemia.
13
Which cardiovascular risk is MOST associated with targeting hemoglobin levels above 13 g/dL with ESA therapy?
A) Ventricular arrhythmias
B) Stroke and thrombotic events
C) Bradycardia
D) Myocardial infarction
Correct Answer: B
Evidence from Clinical Trials: TREAT and CHOIR trials demonstrated that targeting higher hemoglobin levels (greater than 13 g/dL) with ESA therapy significantly increases risk of stroke, thrombosis, and cardiovascular events. This is why current guidelines recommend targeting hemoglobin 10-11.5 g/dL and avoiding ESA initiation when hemoglobin is above ten grams per deciliter. While myocardial infarction risk may also be increased, stroke and thrombotic complications are the most prominent risks. ESAs increase blood viscosity and may promote thrombosis through multiple mechanisms.
Evidence from Clinical Trials: TREAT and CHOIR trials demonstrated that targeting higher hemoglobin levels (greater than 13 g/dL) with ESA therapy significantly increases risk of stroke, thrombosis, and cardiovascular events. This is why current guidelines recommend targeting hemoglobin 10-11.5 g/dL and avoiding ESA initiation when hemoglobin is above ten grams per deciliter. While myocardial infarction risk may also be increased, stroke and thrombotic complications are the most prominent risks. ESAs increase blood viscosity and may promote thrombosis through multiple mechanisms.
14
For a patient with CKD G5 on hemodialysis, what are the target iron parameters?
A) Ferritin greater than 50 ng/mL, TSAT greater than 15%
B) Ferritin 200-500 ng/mL, TSAT greater than 30%
C) Ferritin greater than 1000 ng/mL, TSAT greater than 50%
D) Ferritin 100-200 ng/mL, TSAT 20-25%
Correct Answer: B
Dialysis Iron Targets: For hemodialysis patients receiving ESA therapy, target ferritin 200-500 ng/mL and TSAT greater than thirty percent to ensure adequate iron for erythropoiesis. Avoid ferritin greater than 500-800 ng/mL due to iron overload risk and potential for increased infection and cardiovascular complications. Most dialysis patients require IV iron supplementation due to ongoing blood losses during dialysis, impaired GI absorption, and high erythropoietin demand from ESA therapy. IV iron is typically administered during dialysis sessions.
Dialysis Iron Targets: For hemodialysis patients receiving ESA therapy, target ferritin 200-500 ng/mL and TSAT greater than thirty percent to ensure adequate iron for erythropoiesis. Avoid ferritin greater than 500-800 ng/mL due to iron overload risk and potential for increased infection and cardiovascular complications. Most dialysis patients require IV iron supplementation due to ongoing blood losses during dialysis, impaired GI absorption, and high erythropoietin demand from ESA therapy. IV iron is typically administered during dialysis sessions.
15
Which medication can worsen anemia in CKD patients and should be avoided when possible?
A) ACE inhibitors
B) Calcium channel blockers
C) Proton pump inhibitors (PPIs)
D) Statins
Correct Answer: C
PPI Effect on Anemia: Proton pump inhibitors reduce iron absorption by decreasing gastric acid needed to convert ferric iron to absorbable ferrous form. Long-term PPI use can contribute to iron deficiency, especially in CKD patients who already have impaired iron absorption. If PPIs are necessary, consider using lowest effective dose and monitoring iron parameters more closely. May need IV iron if oral iron ineffective. ACE inhibitors can cause mild hemoglobin reduction but should not be discontinued as renal benefits outweigh this effect. Calcium channel blockers and statins do not significantly affect hemoglobin.
PPI Effect on Anemia: Proton pump inhibitors reduce iron absorption by decreasing gastric acid needed to convert ferric iron to absorbable ferrous form. Long-term PPI use can contribute to iron deficiency, especially in CKD patients who already have impaired iron absorption. If PPIs are necessary, consider using lowest effective dose and monitoring iron parameters more closely. May need IV iron if oral iron ineffective. ACE inhibitors can cause mild hemoglobin reduction but should not be discontinued as renal benefits outweigh this effect. Calcium channel blockers and statins do not significantly affect hemoglobin.
📝 Case Summary & Clinical Pearls
🔑 Key Clinical Pearls:
Iron First, Then ESA: Always correct iron deficiency before starting ESA therapy. Target ferritin greater than 100-200 ng/mL and TSAT greater than twenty percent.
Target Hemoglobin 10-11.5 g/dL: Never target "normal" hemoglobin. Levels above 11.5 g/dL increase stroke and thrombosis risk without additional benefit.
Watch for Functional Iron Deficiency: High ferritin with low TSAT indicates functional iron deficiency requiring IV iron despite elevated ferritin.
IV Iron More Effective in Advanced CKD: For eGFR less than thirty, IV iron is more effective and better tolerated than oral iron.
Transfuse Judiciously: Reserve transfusions for hemoglobin less than seven grams per deciliter in stable patients. ESA and iron are preferred for chronic management.